1-(diiodomethyl)sulfonyl-4-methyl benzene: RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 62738 |
| CHEMBL ID | 1884140 |
| SCHEMBL ID | 21818 |
| MeSH ID | M0205252 |
| Synonym |
|---|
| benzene, 1-[(diiodomethyl)sulfonyl]-4-methyl- |
| diiodomethyl p-tolyl sulfone |
| einecs 243-468-3 |
| benzene, 1-((diiodomethyl)sulfonyl)-4-methyl- |
| p-((diiodomethyl)sulphonyl)toluene |
| amical 48 |
| 1-(diiodomethyl)sulfonyl-4-methyl benzene |
| 1-((diiodomethyl)sulfonyl)-4-methylbenzene |
| epa pesticide chemical code 101002 |
| brn 2212639 |
| caswell no. 353b |
| NCGC00163712-01 |
| 1-(diiodomethylsulfonyl)-4-methylbenzene |
| FT-0650296 |
| A814171 |
| iodo-methylsulfonyl-(p-tolyl)-$l^{3}-iodane |
| 20018-09-1 |
| fdj36qmi3h , |
| unii-fdj36qmi3h |
| hsdb 8033 |
| AKOS015890443 |
| 4-(diiodomethylsulfonyl)toluene |
| diiodomethyl 4-methylphenyl sulfone |
| diiodomethyltolylsulfone [inci] |
| 4-(diiodomethylsulfonyl) toluene |
| diiodomethyltolylsulfone |
| diiodomethyl 4-tolyl sulfone |
| diiodomethyl p-tolyl sulphone |
| 4-tolyl diiodomethyl sulfone |
| sulfone, diiodomethyl p-tolyl |
| SCHEMBL21818 |
| diiodomethyl-p-tolylsulphone |
| cas-20018-09-1 |
| NCGC00356977-01 |
| dtxcid1012541 |
| dtxsid3032541 , |
| tox21_303744 |
| CHEMBL1884140 |
| c8h8i2o2s |
| p-[(diiodomethyl)sulphonyl]toluene |
| mfcd00072720 |
| 66456-97-1 |
| tolyl diiodomethyl sulfone |
| DS-5005 |
| Q11310933 |
| 1-[(diiodomethyl)sulfonyl]-4-methylbenzene |
| CS-W019145 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " These data were compared to iodide toxicokinetic results of a reproductive toxicity study for DIMPTS (80 mg/kg/day) and MPTS (32 mg/kg/day), where DIMPTS was toxic to dams and pups, while MPTS caused no toxicity." | ( Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME. Brzak, KA; Clark, AJ; Saghir, SA; Staley, JL; Yano, BL; Zablotny, CL, 2012) | 0.38 |
| " This MOA evaluation also addresses the potential for toxicity and adverse health outcomes during critical windows of development for different tissues." | ( Diiodomethyl-p-tolylsulfone: evaluation of the mode of action for reproductive toxicity. Poole, A; Saghir, SA, 2012) | 0.38 |
| " The toxicological effects noted in the two mammalian species are consistent with the principal toxic effects of iodine, and are proposed to arise from release of iodide from the DIMPTS molecule with toxic sequelae." | ( Subchronic toxicity and genotoxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in laboratory animals. Berdasco, NA; Pitt, JA; Saghir, SA; Spencer, PJ, 2012) | 0.38 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Dermally applied (14)C-DIMPTS remained undetectable in plasma with bioavailability ≈ 7%, only 5-7% of the dose was recovered in urine." | ( Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME. Brzak, KA; Clark, AJ; Saghir, SA; Staley, JL; Yano, BL; Zablotny, CL, 2012) | 0.38 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 39.9149 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 28.8241 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 7.3740 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 54.9410 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 54.9410 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.8267 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 24.3563 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 33.6053 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378; AID1259394 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 40.6228 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 76.9588 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 33.9972 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 8.6922 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.8253 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 65.7721 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 47.3935 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID588527 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 19.3312 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 25.8950 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 28.3709 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 37.6460 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 17.4882 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID588543 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 29.9383 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385; AID1259393; AID1259395 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 14.0368 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 13.3845 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 14.8266 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 12.1972 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 21.3145 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 12.1972 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 13.6854 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 13.6854 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 28.1838 | 0.0158 | 23.5273 | 44.6684 | AID651778 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
| nucleus | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
| nucleoplasm | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
| chromatin | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
| nucleus | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||